Non-Hodgkin Lymphoma | Specialty

Resistance to BTK Inhibitors in B-Cell Malignancies

March 4th 2019

BTK Inhibitors Explored in B-Cell Malignancies

March 4th 2019

Targeting BTK in B-Cell Malignancies

March 4th 2019

Genomic Profiling in Chronic Lymphocytic Leukemia

March 4th 2019

Diagnosing Waldenstrom Macroglobulinemia

March 4th 2019

Dr. Casulo on Predicting Outcomes in Follicular Lymphoma

March 2nd 2019

Carla Casulo, MD, discusses several different factors that can help predict outcomes in patients with follicular lymphoma.

Dr. Gordon on Chemotherapy-Free Regimens in Follicular Lymphoma

February 28th 2019

Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor of medicine (hematology and oncology), Northwestern University Feinberg School of Medicine, discussed emerging chemotherapy-free regimens in the treatment of patients with follicular lymphoma.

Pivotal Data Refine Treatment Strategies in Hodgkin Lymphoma and Follicular Lymphoma

February 27th 2019

Leo I. Gordon, MD, discussed these recent updates in Hodgkin lymphoma and non–Hodgkin lymphoma and pointed to research on the horizon.

FDA Grants Lenalidomide/Rituximab Priority Review for Indolent Non-Hodgkin Lymphoma

February 27th 2019

The FDA has granted a priority review designation to a supplemental new drug application for the R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) for use in patients with previously treated follicular lymphoma and marginal zone lymphoma.

FDA Grants Polatuzumab Vedotin Priority Review for DLBCL

February 19th 2019

The FDA has granted a priority review designation to polatuzumab vedotin for use in combination with bendamustine and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

FDA Grants Umbralisib Breakthrough Designation for Marginal Zone Lymphoma

January 22nd 2019

The FDA has granted umbralisib (TGR-1202) a breakthrough therapy designation for the treatment of adult patients with marginal zone lymphoma who have received 1 prior anti-CD20 regimen.

Cause for Optimism in Follicular Lymphoma Treatment

January 19th 2019

Emerging Therapies and Combinations

January 19th 2019

Immunotherapeutic Agents Against Follicular Lymphoma

January 19th 2019

Potential of R2 Regimen in Treating Follicular Lymphoma

January 19th 2019

Strategies for Therapeutic Sequencing Agents

January 19th 2019

Long-Term Efficacy and Safety of Copanlisib

January 19th 2019

Use of PI3K Inhibitors in Relapsed Follicular Lymphoma

January 19th 2019

Third-Line Treatments and Transplantation

January 19th 2019

Treating Relapsed or Refractory Follicular Lymphoma

January 19th 2019